reports
LivaNova Reports First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis First-quarter U.S. GAAP...
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company’s development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. “I am very pleased to welcome Ahmet to the LivaNova team. At...
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incide...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023. The incident resulted in a disruption to portions of the Company’s information technology systems. Promptly after detecting the issue on November 19, 2023, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Com...
ICU Medical Announces Time of First Quarter 2024 Earnings Conference C...
ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. The cal...
LivaNova to Announce First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2024 results prior to the call. A live audiocast will be accessible at . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial (if dialing from within the U.S.) or (if dialing from outside the U.S.). The...
LivaNova Announces a Positive Predictive Outcome of Trial Success in i...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its , has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated. This means there is a greater than 97.5% probability that the OSPREY trial will successfully meet its primary endpoint. OSPREY is a prospective, multi-center, randomized controlled open-label trial demonstrating the safety and effectiveness of the aura6000™ Hypoglossal Nerve Stimulator System versus a no stimulation control in subjects with moderate to severe obstructive sleep ...
Boston Scientific Corp: 1 director
A director at Boston Scientific Corp sold 14,506 shares at 66.450USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
ICU Medical to Present at the KeyBanc Life Sciences & MedTech Investor...
ICU Medical to Present at the KeyBanc Life Sciences & MedTech Investor Forum SAN CLEMENTE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the KeyBanc Life Sciences & MedTech Investor Forum being held virtually March 19-20, 2024. ICU Medical’s presentation will be on Wednesday, March 20, 2024 at 11:15 a.m. PT (2:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, March 20, 2024. The pr...
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the “notes”) to be issued in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, LivaNova has granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes ...
LivaNova Announces Proposed Private Offering of $300 Million of Conver...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors. LivaNova also intends to grant to the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and in...
LivaNova to Present at the Barclays Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 10:45 a.m. Eastern Time on Tuesday, March 12. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on ...
ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional ...
ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional Investors Conference SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the Raymond James 45th Annual Institutional Investors Conference being held in Orlando, Florida, March 3-6, 2024. ICU Medical’s presentation will be on Monday, March 4, 2024 at 4:30 a.m. PT (7:30 a.m. ET). Company management will also be participating in one-on-one meetings o...
- Dave Nicoski
- Ross LaDuke
LIVN LIVANOVA PLC
INT WORLD FUEL SERVICES CORPORATION
HBI HANESBRANDS INC.
GPC GENUINE PARTS COMPANY
DORM DORMAN PRODUCTS INC.
DG DOLLAR GENERAL CORPORATION
BBW BUILD-A-BEAR WORKSHOP
BBY BALFOUR BEATTY PLC
LOK LOK 'N STORE GROUP PLC
OXM OXFORD INDUSTRIES INC.
UA UNDER ARMOUR INC. CLASS C
CLF CLEVELAND-CLIFFS INC
EYE NATIONAL VISION HOLDINGS
RCUS ARCUS BIOSCIENCES
RVLV REVOLVE GROUP
STOK STOKE THERAPEUTICS
RPRX ROYALTY PHARMA PLC CLASS A
LPI LAREDO PETROLEUM INC.
HPK HIGHPEAK ENERGY INC (A)
MRVI MARAVAI LIFESCIENCES HOLDINGS
ATNM ACTINIUM PHARMACEUTICALS INC
LMND LEMONADE INC
ACVA ACV AUCTIONS INC
LYEL LYELL IMMUNOPHARMA INC
AMLX AMYLYX PHARMACEUTICALS INC
SCLX SCILEX HOLDING COMPANY
HIPO HIPPO HLDGS INC
ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal ...
ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance SAN CLEMENTE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023. Fourth Quarter 2023 Results Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2023 was $171.6 million, as compared to $174.9 million in the...
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights1 Fourth-quarter revenue of $310.1 million increased 12.8 percent on a reported basis and 11.9 percent on a constant-currency basis, as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share was $0.30 and adjusted diluted earnings per share was $0.87 Full-year 2023 revenue of $1.15 billion increased 12.9 percent on a ...
ICU Medical Announces Time of Fourth Quarter 2023 Earnings Conference ...
ICU Medical Announces Time of Fourth Quarter 2023 Earnings Conference Call SAN CLEMENTE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2023 earnings release and conference call. The Company will release its fourth quarter 2023 results on Tuesday, February 27th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, February 27t...
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of Directors, effective March 1, 2024. Makatsaria most recently served as Company Group Chairman at Johnson & Johnson MedTech, leading its global Ethicon surgery business. “Vlad is a respected leader in the medical device industry with a proven reputation for delivering results, driving innovation and building great teams,” said Bill Kozy, LivaNova Board ...
LivaNova to Wind Down Advanced Circulatory Support Business Unit
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support (ACS) Business Unit to increase the Company’s strategic focus on its core Cardiopulmonary (CP) and Neuromodulation Business Units. ACS generated approximately 4% of net revenue for the nine months ended September 30, 2023. The wind down is anticipated to be complete by the end of 2024. The Company will retain all ACS standalone cannulae products and related accessories, including Pro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.